Literature DB >> 8054770

A clinical analysis of small-sized lung cancer with advanced disease.

J Shimizu1, Y Hayashi, M Oda, S Murakami, Y Arano, K Morita, K Kobayashi, K Ietsugu, Y Watanabe.   

Abstract

A clinical analysis of small-sized lung cancers with advanced disease was conducted on a total of 58 patients: 34 diagnosed as T1N2, 6 as T1N3, 9 as T1M1, and 9 as T4 due to pleural dissemination. The cumulative 5-year survival rate after surgery for the 34 patients with a T1N2 lesion was 17.4%. Of these 34 patients, 24 underwent a curative operation resulting in a 5-year survival rate of 23.7%, but the remaining 10 patients, who underwent a non-curative operation, had a 5-year survival rate of 0%. Extended lymph node dissection for N3 disease has only been performed in recent years, so it is not yet clear whether it will affect the survival rate or not. T4 disease due to pleural dissemination and T1M1 disease associated with intrapulmonary metastasis encountered at thoracotomy could be expected to have relatively long-term survival with the combined use of systemic immunochemotherapy after surgery. In cases diagnosed as T4 due to pleural dissemination, we have recently employed resection of the primary lesion with parietal pleurectomy as the standard operative procedure. For cases of T1M1 with intrapulmonary metastasis confined to the same lobe as the primary lesion, a lobectomy is usually performed, while for cases with intrapulmonary metastasis extending to another lobe, a lobectomy with enucleation of metastatic nodules or pneumonectomy is most often performed instead of an exploratory thoracotomy.

Entities:  

Mesh:

Year:  1994        PMID: 8054770     DOI: 10.1007/bf01676879

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  9 in total

1.  Aggressive surgical intervention in N2 non-small cell cancer of the lung.

Authors:  Y Watanabe; J Shimizu; M Oda; Y Hayashi; S Watanabe; Y Tatsuzawa; T Iwa; M Suzuki; T Takashima
Journal:  Ann Thorac Surg       Date:  1991-02       Impact factor: 4.330

2.  The significance of ipsilateral mediastinal lymph node metastasis (N2 disease) in non-small cell carcinoma of the lung. A commentary.

Authors:  T W Shields
Journal:  J Thorac Cardiovasc Surg       Date:  1990-01       Impact factor: 5.209

3.  [Clinical analyses of patients with lung cancer associated with intrapulmonary metastasis].

Authors:  Y Watanabe; H Kobayashi; T Magara; H Sato; T Iwa
Journal:  Rinsho Kyobu Geka       Date:  1984-07

4.  Multiple primary lung cancers.

Authors:  N Martini; M R Melamed
Journal:  J Thorac Cardiovasc Surg       Date:  1975-10       Impact factor: 5.209

Review 5.  Neoadjuvant therapy of stage III non-small cell lung cancer.

Authors:  L H Einhorn
Journal:  Ann Thorac Surg       Date:  1988-09       Impact factor: 4.330

6.  The importance of surgery to non-small cell carcinoma of lung with mediastinal lymph node metastasis.

Authors:  T Naruke; T Goya; R Tsuchiya; K Suemasu
Journal:  Ann Thorac Surg       Date:  1988-12       Impact factor: 4.330

7.  Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer.

Authors:  L P Faber; C F Kittle; W H Warren; P D Bonomi; S G Taylor; S Reddy; M S Lee
Journal:  Ann Thorac Surg       Date:  1989-05       Impact factor: 4.330

8.  Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph node metastases.

Authors:  N Martini; B J Flehinger; M B Zaman; E J Beattie
Journal:  Ann Surg       Date:  1983-09       Impact factor: 12.969

9.  The effects of preoperative chemotherapy on the resectability of non-small cell lung carcinoma with mediastinal lymph node metastases (N2 M0).

Authors:  N Martini; M G Kris; R J Gralla; M S Bains; P M McCormack; L R Kaiser; M E Burt; M B Zaman
Journal:  Ann Thorac Surg       Date:  1988-04       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.